February 7, 2020 (v1)
Publication
To date, the standard approach to metastatic melanoma with classic chemoterapeutic agents has been unsuccessful. In the last 15 years, he identification of mutations in BRAF genes, such as BRAFV600E, led to the development of BRAF mutant target therapies with small biological inhibitors (i.e. Vemurafenib, PLX4032) that specifically block the...
Uploaded on: April 14, 2023